Microbot Medical Inc. (NASDAQ: MBOT)

Microbot Medical Inc., also known as MBOT, operates in the medical device industry with a focus on next-generation robotic endoluminal surgery devices. The company's primary operations involve the research, design, and development of innovative medical technologies, specifically targeted at the minimally invasive surgery space. With its headquarters in Israel, Microbot Medical serves both local and international markets.

The company generates revenue through the development and commercialization of its products, including the LIBERTY Endovascular Robotic Surgical System, NovaCross, and other technologies. The LIBERTY Endovascular Robotic Surgical System is a fully disposable robot designed for endovascular interventional procedures, such as cardiovascular, peripheral, and neurovascular procedures. This system provides several advantages, such as a compact design, remote operation capabilities, and reduced radiation exposure, making it an attractive solution for medical professionals.

NovaCross is an intraluminal revascularization device with an anchoring mechanism and integrated microcatheter, designed to be used in conjunction with the LIBERTY Endovascular Robotic Surgical System. Other technologies and platforms under development at Microbot Medical have been ceased or returned to their respective intellectual property owners, such as CardioSert and Technion Research and Development Foundation.

Microbot Medical competes in the minimally invasive surgery market, which is expected to grow from $24 billion in 2020 to $42 billion in 2026, representing a CAGR of 9.85%. The market for surgical devices, including ablation, electrosurgery, and medical robotic systems, accounts for the largest share of revenue and is expected to show the highest rate of growth. The main competitor to the LIBERTY Endovascular Robotic Surgical System is the CorPath GRX vascular robotics system by Corindus Vascular Robotics, a Siemens Healthineers company. Other competitors include Robocath, LN Robotics, and Endoways.

Microbot Medical's competitive advantage lies in its robust intellectual property portfolio, consisting of 12 patents issued/allowed and 47 patent applications pending worldwide, as well as 10 design patents issued/allowed and 5 design patents pending worldwide. The company relies on this intellectual property, along with trade secrets, trademarks, technical innovations, laws of unfair competition, and various licensing agreements, to ensure its future growth, build its competitive position, and protect its technology.

In terms of customer base, the document does not provide specific names. However, the company's products and services cater primarily to medical professionals and facilities in need of advanced, minimally invasive surgical solutions.